Skip to content

Intraoperatieve fluorescente beeldvorming van borsttumoren.

Intraoperative fluorescent imaging of breast cancer.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22328
Enrollment
40
Registered
2012-11-21
Start date
2012-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Standard breast conserving surgery or ablation procedure will be performed. During surgery or 4 hours before surgery, the near-infrared dye Methylene blue (MB) will be injected and the breast carcinom

Sponsors

Leiden University Medical Center (LUMC)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with breast cancer eligible to undergo a resection.

Exclusion criteria

Exclusion criteria: 1. Patients using SSRI's, SNRI's of TCA's; 2. Allergy to methyleen blue, history of severe renal impairment or G6PD-deficiency; 3. Patient pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Primary outcome parameter is the number of identified breast tumors.

Secondary

MeasureTime frame
Secundary parameters are the tumor-to-background ratios measured during surgery and during pathological analysis.

Contacts

Public ContactC.J.H. Velde, van de

Leiden University Medical Center (LUMC), Department of Surgical Oncology, P.O. Box 9600

c.j.h.van_de_velde@lumc.nl+31 (0)71 5262309

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)